Toll Free: 1-888-928-9744

Seattle Genetics, Inc. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Seattle Genetics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Seattle Genetics, Inc. - Product Pipeline Review - 2014', provides an overview of the Seattle Genetics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Seattle Genetics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Seattle Genetics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Seattle Genetics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Seattle Genetics, Inc.'s pipeline products

Reasons to buy

- Evaluate Seattle Genetics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Seattle Genetics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Seattle Genetics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Seattle Genetics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seattle Genetics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Seattle Genetics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Seattle Genetics, Inc. Snapshot 5
Seattle Genetics, Inc. Overview 5
Key Information 5
Key Facts 5
Seattle Genetics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Seattle Genetics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Seattle Genetics, Inc. - Pipeline Products Glance 14
Seattle Genetics, Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Seattle Genetics, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Seattle Genetics, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Seattle Genetics, Inc. - Drug Profiles 18
brentuximab vedotin 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SGN-CD19A 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SGN-CD33A 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SGN-LIV1A 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SGD-2083 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SGN-CD70A 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Seattle Genetics, Inc. - Pipeline Analysis 29
Seattle Genetics, Inc. - Pipeline Products by Target 29
Seattle Genetics, Inc. - Pipeline Products by Route of Administration 31
Seattle Genetics, Inc. - Pipeline Products by Molecule Type 32
Seattle Genetics, Inc. - Pipeline Products by Mechanism of Action 33
Seattle Genetics, Inc. - Recent Pipeline Updates 35
Seattle Genetics, Inc. - Dormant Projects 51
Seattle Genetics, Inc. - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
dacetuzumab 52
lintuzumab 52
SGN-15 52
vorsetuzumab 53
vorsetuzumab mafodotin 53
Seattle Genetics, Inc. - Company Statement 54
Seattle Genetics, Inc. - Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Seattle Genetics, Inc., Key Information 5
Seattle Genetics, Inc., Key Facts 5
Seattle Genetics, Inc. - Pipeline by Indication, 2014 8
Seattle Genetics, Inc. - Pipeline by Stage of Development, 2014 9
Seattle Genetics, Inc. - Monotherapy Products in Pipeline, 2014 10
Seattle Genetics, Inc. - Partnered Products in Pipeline, 2014 11
Seattle Genetics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Seattle Genetics, Inc. - Phase III, 2014 14
Seattle Genetics, Inc. - Phase II, 2014 15
Seattle Genetics, Inc. - Phase I, 2014 16
Seattle Genetics, Inc. - Preclinical, 2014 17
Seattle Genetics, Inc. - Pipeline by Target, 2014 30
Seattle Genetics, Inc. - Pipeline by Route of Administration, 2014 31
Seattle Genetics, Inc. - Pipeline by Molecule Type, 2014 32
Seattle Genetics, Inc. - Pipeline Products by Mechanism of Action, 2014 34
Seattle Genetics, Inc. - Recent Pipeline Updates, 2014 35
Seattle Genetics, Inc. - Dormant Developmental Projects,2014 51
Seattle Genetics, Inc. - Discontinued Pipeline Products, 2014 52
Seattle Genetics, Inc., Subsidiaries 57 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify